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Abstract
Interleukin-6 (IL-6) is a growth factor for normal B cells and
plasma cell-derived malignancies. Here, we show that the IL-6
signaling pathway is also active in a subset of diffuse large B-cell
lymphoma (DLBCL) patients with particularly poor prognosis.
Primary DLBCL cells and DLBCL cell lines expressing IL-6R engraft
and form orthotopic lymphomas in humanized mice that ectopi-
cally produce human IL-6, and in mice reconstituted with a human
immune system. We show that a subset of DLBCL cases have
evolved mechanisms that ensure constitutive activation of the IL-6
signaling pathway, i.e., the expression of both chains of the IL-6R,
the expression of the cytokine itself, and the mutational inactiva-
tion of a negative regulator of IL-6 signaling, SOCS1. IL-6 signaling
promotes MYC-driven lymphomagenesis in a genetically engi-
neered model, and treatment with the IL-6R-specific antibody toci-
lizumab reduces growth of primary DLBCL cells and of DLBCL cell
lines in various therapeutic settings. The combined results uncover
the IL-6 signaling pathway as a driver and negative prognosticator
in aggressive DLBCL that can be targeted with a safe and well-
tolerated biologic.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malig-
nancy of the mature B cell. DLBCL originates from antigen-
exposed B cells that have undergone the germinal center (GC)
reaction (Basso & Dalla-Favera, 2015); one of the disease hall-
marks is its inter-tumoral heterogeneity. Whereas gene expression
profiling has traditionally been used to identify two major subsets
of DLBCL that differ in their cell of origin, i.e., the activated B-cell
and germinal center B-cell subtypes (ABC- and GCB-DLBCL;
Alizadeh et al, 2000; Rosenwald et al, 2002), more recent studies
have distinguished up to four (Schmitz et al, 2018) or five (Cha-
puy et al, 2018) different molecular subtypes based on transcrip-
tional and mutational signatures, somatic copy number
alterations, and structural variants. These subtypes differ strongly
in their response to untailored treatments and survival probability.
In particular, the refined stratification based on genetic abnormali-
ties has led to the differentiation of two subsets of ABC-DLBCL, of
which one is characterized by (co-occurring) MYD88 and CD79B
mutations, extranodal manifestations, a genetic signature of aber-
rant somatic hypermutation driven by activation-induced cytidine
deaminase activity, and a dismal prognosis, whereas the other is
characterized by NOTCH2 and BCL6 mutations and structural
aberrations, respectively, and associated downstream transcrip-
tional signatures, a presumably extrafollicular origin more reminis-
cent of marginal zone lymphoma, and a comparatively superior
prognosis (Chapuy et al, 2018; Schmitz et al, 2018). Similarly,
GCB-DLBCL can be stratified into two subtypes, of which one typi-
cally harbors translocations juxtaposing BCL2 to the IGH enhancer
in combination with frequent mutations of the chromatin modi-
fiers KMT2D, CREBBP, and EZH2, and inactivating PTEN muta-
tions, bears similarities to the genetic landscape of follicular
lymphoma and features a poor prognosis, whereas the other is a
relatively low-risk subtype with mutations in PI3K-, JAK/STAT-,
and MAPK-pathway components and histones (Chapuy et al,
2018; Schmitz et al, 2018).
The current standard of care for DLBCL, irrespective of subtype,
is a combination of chemotherapy and the CD20-targeting antibody
rituximab (R-CHOP; Coiffier et al, 2002; Basso & Dalla-Favera,
2015). Chimeric antigen receptor T-cell therapy was approved in
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2017 for relapsed or refractory DLBCL patients, and produces
durable remissions in 30–40% of these very difficult-to-treat cases,
but is associated with severe side effects (Chow et al, 2018). Other
approved or experimental targeted treatments may be suitable for
specific subsets of patients. For example, the Bruton tyrosine kinase
inhibitor ibrutinib is active in 37% of cases of ABC-DLBCL (Wilson
et al, 2015). The susceptibility to ibrutinib is limited to patients with
tumors exhibiting both CD79B and MYD88 (L265P) mutations
(Wilson et al, 2015), which are characterized by the formation of a
multiprotein supercomplex comprising MYD88, TLR9, and the BCR
that co-localizes with mTOR on endolysosomes and drives pro-
survival NF-jB and mTOR signaling (Phelan et al, 2018). Other
experimental compounds that are currently tested in DLBCL patients
include lenalidomide, which appears to be preferentially active in
the ABC-DLBCL subset of patients (Hernandez-Ilizaliturri et al,
2011; Vitolo et al, 2014), and the proteasome inhibitor bortezomib
(Ruan et al, 2011; Offner et al, 2015; Leonard et al, 2017).
Whereas a detailed picture is now emerging of the heterogenous
genetic landscape of DLBCL due to huge multi-omics profiling
efforts performed on hundreds of patients, the development of suit-
able mouse models that would allow for predictive pre- or co-clin-
ical testing is woefully lagging behind. Preclinical testing is done
using ectopic xenotransplantation models and a small selection of
cell lines that are of limited predictive value; primary patient mate-
rial is notoriously difficult to grow in vitro and will not engraft read-
ily in immunocompromised mouse strains. The available genetic
lymphoma models, mostly taking advantage of aberrant MYC or
BCL2 overexpression in the B-cell compartment, fail to capture the
heterogeneity of the human disease. Here, we show that a geneti-
cally humanized mouse strain, the MISTRG mouse, and its deriva-
tives either expressing human IL-6 or reconstituted with a normal
human immune system lend themselves to the generation of conve-
nient, rapid-onset orthotopic models that feature tumor engraftment
and growth in both lymphoid and non-lymphoid tissues. When
combined with in vivo optical imaging system (IVIS) technology, the
models allow for the monitoring over time of the tumor burden,
tumor dynamics and tissue tropism, clinical symptoms, and treat-
ment responses, not only of cell lines but also of primary patient
material. The orthotopic MISTRG model has allowed us to uncover
a previously unappreciated dependence of a subset of DLBCL on the
IL-6 signaling pathway, which can be exploited therapeutically with
a specific monoclonal antibody that is approved for other unrelated
indications. Biomarkers that may guide treatment decisions include
the tumor cell-intrinsic expression of a functional IL-6 receptor and
the constitutive phosphorylation of the downstream transcription
factor STAT3, which can be assessed by routine flow cytometric or
immunohistochemical testing. In conclusion, we describe here a
new pathogenetic pathway that is active and druggable in a subset
of high-risk DLBCL patients.
Results
DLBCL cell lines engraft in lymphoid and non-lymphoid tissues of
MISTRG mice
We have reported recently that the DLBCL cell lines U-2932
(Hashwah et al, 2017) and RC-K8 (Stelling et al, 2018) engraft in
the bone marrow and/or spleen of MISTRG mice within 4 weeks of
their intravenous administration. To further refine—and increase
the versatility of—this model, we engineered the DLBCL cell lines
U-2932, RC-K8, and RIVA to stably express the green fluorescent
protein ZsGreen as well as firefly luciferase, which enabled us to
visualize their engraftment over time as well as their tissue tropism
using IVIS. All three cell lines showed distinct engraftment dynam-
ics, with RC-K8 cells growing more slowly than the other two, and
showing an almost exclusive preference for the jaw bone that was
not observed with the other cell lines (Fig 1A–C). U-2932 and RIVA
cells colonized the hip and long bones of the legs as judged by their
IVIS signal (Fig 1A–C). A careful whole-body analysis through a
combination of IVIS of explanted organs (representative IVIS
images shown in Fig EV1A) with macroscopic inspection at the
study endpoint further revealed that all three cell lines rather
consistently colonize the lungs, kidneys, liver, and reproductive
tract of both male and female MISTRG mice (Fig 1D). The flow
cytometric quantification of DLBCL cell engraftment in the bone
marrow of femur and tibia and in jaw bone marrow (in the case of
RC-K8) and spleen revealed that a substantial fraction of leukocytes
in both tissues were of human (i.e., DLBCL cell) origin, i.e.,
hCD45- or hCD19-positive, and had also retained their ZsGreen
signal during in vivo growth (Fig 1E–G). In the time frame of up to
6 weeks after tumor cell injection assessed here, DLBCL cell
engraftment was accompanied by clinical symptoms in only a small
fraction (< 20%) of mice; if they occurred, symptoms included
weight loss and progressive paralysis of the hind legs, which in
some instances could be attributed to tumor growth in close prox-
imity to the spinal cord. In conclusion, MISTRG mice represent a
highly permissive host strain for orthotopic DLBCL engraftment that
can be monitored over time using IVIS, and that to some extent
recapitulates hallmarks of human DLBCL in terms of tissue tropism
and aggressiveness.
Reconstitution of MISTRG mice with cord blood hematopoietic
stem cells facilitates DLBCL growth in subcutaneous and
orthotopic models
MISTRG mice express several human cytokines and growth factors
under the control of their endogenous murine regulatory elements,
which not only facilitates DLBCL cell engraftment as shown above,
but also permits their reconstitution with a normal human immune
system from cord blood-derived hematopoietic stem and progenitor
cells (HSPCs; Rongvaux et al, 2014). We speculated that chimeric
mice harboring a normal human immune system might support
DLBCL engraftment even better than their un-reconstituted counter-
parts. To assess a possible benefit of a normal human immune
system for DLBCL growth, we intrahepatically reconstituted
newborn mice with CD34+ human HSPCs, allowed the human cells
to engraft for 6–8 weeks, and subsequently transplanted the mice
subcutaneously or orthotopically with U-2932 or RC-K8 cells. The
reconstitution efficiency of the mice varied substantially, as assessed
at the study endpoint, in both the bone marrow (20–90% human
cells among all CD45+ leukocytes) and the blood (1–20%; Fig 2A).
Mice with a reconstitution efficiency below 5% were considered as
un-reconstituted. A detailed multi-color flow cytometric analysis of
human leukocytes in the bone marrow confirmed that HSPCs in
MISTRG mice give rise to the full spectrum of leukocytes that is
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Figure 1. DLBCL cell lines engraft and form orthotopic lymphomas in MISTRG mice that can be traced by luciferase expression.
A–C A total of 1 × 107 ZsGreen- and luciferase-expressing U-2932, RC-K8, and RIVA cells were intravenously injected into 6-week-old male (M) and female (F) MISTRG
mice and monitored weekly using IVIS for at least four and up to 3 weeks. The color scales on the right indicate the radiance, i.e., the sum of the photons per
second from each pixel inside the ROI/number of pixels (photons/s/cm2/sr).
D The frequency of involvement of the indicated tissues is shown for one cohort of mice and is representative of two independently analyzed cohorts per cell line.
E Gating strategy for the identification of U-2932 cells residing in spleen and bone marrow, among all leukocytes in these organs. Cells were stained for human and
mouse CD45. Very few hCD45+ U-2932 cells were detectable in the spleen, whereas their frequencies were much higher in the bone marrow (BM). In BM, > 90% of
U-2932 cells were positive for ZsGreen. The green curve shows U-2932 cells recovered from BM, overlayed with unlabeled U-2932 cells grown in vitro (gray curve).
F, G Frequencies of human lymphoma cells, as judged by hCD45 expression, among all (human and mouse, h + m) CD45+ leukocytes in the spleen (S), femoral bone
marrow (BM), and jaw bone marrow (JB) at the study endpoint of the mice shown in (D) (4 weeks post-injection for U-2932, 5 weeks p.i. for RIVA, and 6 weeks p.i.
for RC-K8).
Data information: Data in (A–G) are representative of at least two independently conducted studies per cell line. In the study shown, n = 7 (RIVA), 8 (U-2932), and
9 (RC-K8) mice. Horizontal lines indicate medians. Statistics do not apply here.
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found in humans (Fig 2B; Rongvaux et al, 2014). While CD20+ B
cells dominated in the bone marrow, we were also able to readily
detect CD3+ T cells, CD33+ myeloid cells, and NKp46+ NK cells
(Fig 2B, gating strategy in Fig EV2A). Interestingly, reconstituted
mice exhibited larger and heavier tumors over time and at the study
endpoint than their un-reconstituted counterparts when trans-
planted subcutaneously with U-2932 cells (Figs 2C and D, and
EV2B), with reconstitution efficiencies correlating directly with the
tumor burden at the study endpoint (Fig 2E). We speculated that
either human CD4+ T cells or human myeloid cells might be
contributing to subcutaneous DLBCL growth in this model;
however, neither the depletion of CD4+ T cells nor the neutraliza-
tion of the myeloid cell-specific chemokine CCL2 with specific anti-
bodies had a discernible effect on tumor growth in the
subcutaneous model (Fig EV2C and D).
We next assessed a possible benefit of HSPC humanization on
the orthotopic growth of intravenously transplanted U-2932 cells;
indeed, we detected higher frequencies of U-2932 cells in the bone
marrow of reconstituted relative to un-reconstituted mice, and
some reconstituted animals showed involvement of the spleen
(Figs 2F and G, and EV2E). The same general trend was observed
with RC-K8 cells, which also showed superior engraftment in the
bone marrow as a consequence of HSPC humanization, but—in
contrast to U-2932 cells—no spleen involvement (Fig 2F and G).
The higher tumor burden in the bone marrow of RC-K8-trans-
planted mice was readily visible also by IVIS (Fig 2H). Reconsti-
tuted mice exhibited non-lymphoid tissue involvement more
frequently than un-reconstituted mice, with the exception of lungs
in the RC-K8 model (Fig 2I), and a substantial fraction of reconsti-
tuted mice transplanted with RC-K8 cells developed disease-related
clinical symptoms such as weight loss and hind leg paralysis
(Fig 2J). The combined results from the two (ectopic and ortho-
topic) models and the two cell lines indicate that non-malignant
human leukocytes can support DLBCL engraftment and growth at
lymphoid and non-lymphoid sites.
Human IL-6 promotes the engraftment and growth of IL-6R+
DLBCL cells
Interleukin-6 (IL-6) is a well-documented growth factor and thera-
peutic target in plasma cell myeloma, and MISTRG mice that have
been modified with an additional knock-in allele encoding human
IL-6 (MISTRG6) support multiple myeloma engraftment and growth
(Das et al, 2016). To examine whether the humanization of IL-6,
which lacks species cross-reactivity (Kishimoto, 2005), would
provide critical signals necessary for DLBCL growth and survival,
we injected luciferase-expressing RC-K8 or U-2932 cells into
MISTRG and MISTRG6 mice, compared their growth kinetics over
time by IVIS, and assessed human cell engraftment by flow cytomet-
ric analysis at the study endpoint. RC-K8 cells engrafted earlier and
grew faster in the bones of MISTRG6 mice than in their MISTRG
(non-IL-6-expressing) counterparts (Fig 3A); the growth advantage
due to IL-6 provision was also evident at the study endpoint in both
bone marrow and spleen (Fig 3B and C). Several of the MISTRG6
mice, but none of the MISTRG mice harboring RC-K8 cells, devel-
oped disease-related symptoms such as hind leg paralysis; tissue
involvement as judged by macroscopic evaluation or ex vivo IVIS
was observed mostly in MISTRG6 mice (Fig 3D and E). The
differences between the two host strains were not nearly as obvious
upon injection of U-2932 cells; there was no discernible difference
in the tumor load in the bone marrow or peripheral tissues,
although spleens were only colonized in (some) MISTRG6 and not
in MISTRG mice (Fig 3A–E). To assess whether differential expres-
sion of the IL-6 receptor could possibly explain the differences in
terms of IL-6 dependence observed between the two cell lines, we
assessed its surface expression by flow cytometry. Indeed, only RC-
K8, but not U-2932, cells strongly expressed the IL-6 receptor a-
chain CD126 (Fig 3F). To address whether the growth advantage of
RC-K8 cells in MISTRG6 mice could indeed be attributed to CD126
expression, we targeted the second exon of the corresponding gene
IL6R by CRISPR, which resulted in the complete loss of CD126
surface expression (Fig EV3A). RC-K8 cells that had lost CD126
expression colonized MISTRG6 bone marrow somewhat less effi-
ciently than their wild-type counterparts (Fig EV3B). The differential
benefit of the two examined DLBCL cell lines from IL-6 provision
thus mirrors the benefit conferred by human immune cell reconsti-
tution (Fig 2). Indeed, we are able to detect hIL-6 in the serum of
HSPC-reconstituted mice, albeit at lower levels than in serum from
MISTRG6 mice (Fig EV3C). Surface expression of the IL-6 receptor
CD126 appears to contribute to the differential growth of RC-K8 and
U-2932 cells in MISTRG and MISTRG6 mice.
Reconstitution of MISTRG mice with cord blood hematopoietic
stem cells, or knock-in of hIL-6, promotes primary
DLBCL engraftment
Primary DLBCL cells are notoriously difficult to engraft in mice;
published protocols require surgery and implantation of tumor
material under the kidney capsule (Chapuy et al, 2016), which
creates a model that is technically challenging, not scalable, not
orthotopic, and does not lend itself to serial transplantation or drug
testing. We speculated that MISTRG or MISTRG6 mice, or MISTRG
mice harboring a normal human immune system, might be permis-
sible to primary DLBCL cell engraftment and growth. To this end,
we obtained the bone marrow aspirate of a patient with stage IVBE
ABC-DLBCL with extranodal manifestations in the liver, an IPI
score of 5, a diagnosis of splenomegaly, and approximately 7%
infiltration of the bone marrow with tumor cells. All available
tumor cells (100,000) were intravenously injected into a MISTRG6
recipient, where they engrafted in the bone marrow and spleen
within a time frame of 8 weeks. Spleen cells from this donor
mouse were serially transplanted into a cohort of MISTRG and
MISTRG6 mice, and engrafted exclusively in the latter strain,
where they formed splenic lymphomas with bone marrow involve-
ment that were histologically and immunophenotypically indistin-
guishable from the patient tumor (Fig 4A–E). None of the MISTRG
recipients lacking expression of IL-6 showed evidence of
lymphoma engraftment (Fig 4A–E). Interestingly, MISTRG recipi-
ents that had been reconstituted at birth with a normal human
immune system promoted lymphoma engraftment in the bone
marrow as efficiently as mice expressing IL-6 (Fig 4F).
Immunophenotyping revealed a clonal, lambda light chain-
restricted tumor cell population in all lymphoma-bearing mice
(Fig 4D and F). The primary lymphoma cells used here express
high levels of the IL-6R a-chain and of the signaling chain gp130
and are positive for the phosphorylated form of the signal
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Figure 2. Reconstitution of MISTRG mice with cord blood hematopoietic stem cells confers a growth advantage to xenotransplanted DLBCL cell lines in
ectopic and orthotopic tumor models.
A–E MISTRG mice were reconstituted or not at birth with ~ 200,000 human CD34+ cord blood HSPCs and subcutaneously transplanted with 1 × 107 U-2932 cells at
6 weeks of age. Tumor volumes were recorded over time, and along with tumor weights, at the study endpoint on day 27 post-injection. The reconstitution
efficiency (frequency of human among all human and mouse CD45+ leukocytes) is shown in (A), and the average human leukocyte composition in the bone marrow
of the mice in (A) is shown in (B). Tumor volumes over time are presented in (C) along with tumor weights and volumes at the study endpoint in (D), where each
data point represents one tumor. The reconstitution level directly correlates with the tumor weight at the endpoint (E).
F–J MISTRG mice were reconstituted or not at birth with human CD34+ cord blood HSPCs and intravenously injected with 1 × 107 U-2932 or RC-K8 cells at 6 weeks of
age. The lymphoma burden at the study endpoint was quantified in the spleen (F) and bone marrow (G) by staining for hCD45 and by ZsGreen expression (as well
as hCD19 and hCD20 for U-2932 and RC-K8, respectively), and in the case of RC-K8 cells, also over time by IVIS (H). The frequency of tissue involvement was
assessed by ex vivo IVIS and macroscopic evaluation (I), and the occurrence of clinical symptoms (weight loss, hind leg paralysis) was recorded for each mouse (J).
The x indicates that this mouse was not available for IVIS at the final time point because of premature death.
Data information: Data in (A–E) are pooled from three independent experiments. Data in (F–J) are pooled from two independent experiments per cell line. P-values were
calculated using the Mann–Whitney test and one-way ANOVA (in E). Horizontal lines indicate medians throughout. n is indicated in the figure panels throughout. Tumor
volumes over time are presented in (C) as mean  SD. (E) Tumor weights are presented as boxplots with Tukey whiskers for different reconstitution levels in the bone marrow.
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transducer and activator of transcription STAT3, which mediates
signal transduction downstream of the IL-6R heterodimer (Fig 4G
and H). The expression of both chains of the IL-6R could further
also be detected by qRT–PCR of immunomagnetically enriched
CD19+ B cells from this patient’s bone marrow aspirate (Fig EV3D
and E). To address whether the expression of the IL-6R would
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Figure 3. Genetic IL-6 humanization promotes growth of DLBCL cells that express the IL-6 receptor.
A–E MISTRG and MISTRG6 mice were intravenously injected with 1 × 107 U-2932 or RC-K8 cells at 6 weeks of age and monitored weekly by IVIS until the study
endpoint (A). The lymphoma burden at the study endpoint (6 weeks p.i. for RC-K8 and 4 weeks p.i. for U-2932) was quantified in the spleen (B) and bone marrow
(C) by flow cytometric staining for hCD45 and by ZsGreen expression. The involvement of the indicated tissues as assessed by ex vivo IVIS is shown in (D) (solid
bars, MISTRG; hatched bars, MISTRG6), and mice that have developed clinical symptoms (paralysis of hind legs) are plotted in (E). In (B, C, and E), MISTRG is
abbreviated as M and MISTRG6 as M6.
F Surface expression of the IL-6 receptor a-chain (CD126) as assessed by flow cytometry of U-2932 and RC-K8 cells. Data are representative of two stainings.
Data information: Data in (A–E) are from two independent experiments per cell line; ex vivo IVIS and clinical scoring of U-2932 (in D and E) was performed for only one
experiment, and in vivo IVIS is shown for a subset of mice. Horizontal lines indicate medians throughout. P-values were calculated using the Mann–Whitney test. n is
indicated in the figure panels throughout.
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Figure 4. Human IL-6 and human immune system reconstitution both promote primary orthotopic DLBCL growth.
A–E A total of 1 × 106 primary DLBCL cells obtained by passaging through a MISTRG6 mouse were intravenously injected into MISTRG or MISTRG6 recipients. The
spleen weights (B, representative pictures in (A) are shown along with representative H&E-stained spleen (MISTRG6) and lymph node (patient) sections in (C) and
the lymphoma burden at the study endpoint 8 weeks p.i., as quantified in the spleen and bone marrow in (D and E). Representative flow cytometry plots are
shown in (D) for bone marrow and spleen (MISTRG, MISTRG6). Lymphoma cells were positive for hCD19 and were lambda light chain-restricted (right panels of
MISTRG6). M, MISTRG; M6, MISTRG6. Scale bar in (A), 1 cm. Scale bar in (C), 100 lm.
F MISTRG mice were reconstituted or not at birth with human CD34+ cord blood HSPCs and intravenously injected with 1 × 106 primary DLBCL cells at 6 weeks of
age. The lymphoma burden at the study endpoint was quantified in the bone marrow of reconstituted and un-reconstituted animals by flow cytometric staining
for the indicated surface markers.
G, H Primary lymphoma cells harvested at the study endpoint express the IL-6R a chain (CD126, as assessed by flow cytometry, G) and the signaling chain gp130 (as
assessed by immunohistochemistry, H) and are positive for phosphorylated STAT3 (G). Blue curves, hCD126 or p-STAT3; gray curves, isotype control antibody. Scale
bar in (H), 100 lm.
Data information: Data in (A–E) are pooled from two independent experiments and representative of three experiments. Data in (F) are from one experiment and
representative of two. In (B, E, and F), each symbol represents one mouse and horizontal lines indicate medians. P-values were calculated using the Mann–Whitney test.
n is indicated in the figure panels throughout.
Source data are available online for this figure.
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generally correlate with the propensity for engraftment of primary
human DLBCL cells, we subjected three additional patient samples
to immunomagnetic enrichment followed by qRT–PCR for both IL-
6R chains and transplanted all available cells from each donor (in
some cases, this number was under 100,000 cells) into MISTRG6
mice. Of the three additional examined primary cell samples, only
one tested positive for both IL-6R chains at the transcript level
(Fig EV3D and E). None of the three showed evidence of engraft-
ment in the spleen or bone marrow of MISTRG6 mice in the exam-
ined time frame of 8 weeks (Fig EV3E). These results indicate that
human IL-6 may promote the orthotopic engraftment and growth
of primary DLBCL cells; expression of a functional heterodimeric
IL-6R likely is necessary, but not sufficient, for successful engraft-
ment. Once established, primary DLBCL cells can readily be
passaged in MISTRG6 mice without losing the characteristics of the
human patient material.
DLBCL cells differ in their IL-6 receptor expression
We next set out to examine more systematically whether the
expression of the IL-6R is a common feature of DLBCL cells. In
humans, the functional heterodimeric IL-6R consists of the unique
subunit CD126 mentioned above and a second subunit, the glyco-
protein gp130 (CD130) that is shared with other cytokines includ-
ing IL-11, IL-27, leukemia inhibitory factor, and oncostatin M, and
encodes an intracellular domain required for signal transduction
downstream of the functional IL-6R. We assessed the expression of
both subunits in a panel of 12 DLBCL cell lines that we had at our
disposal. Only two cell lines, the RC-K8 shown above (Fig 3F) and
OCI-Ly3, expressed detectable levels of the IL-6R as assessed by
flow cytometry and qRT–PCR (Fig 5A and B). The expression of
gp130 was difficult to detect by flow cytometry; qRT–PCR results
indicate that gp130 is weakly expressed by all ABC-DLBCL cell
lines, but not by GCB-DLBCL cell lines (Fig 5A–C). This observa-
tion could be confirmed by Western blotting (Fig EV4A). RC-K8
cells express both subunits; this cell line has features of both ABC
and GCB subtypes (Kalaitzidis et al, 2002; Fig 5C). We next
assessed the expression of both chains of the IL-6R in tumor biop-
sies from a cohort of 114 DLBCL patients that were spotted on
tissue microarrays. Staining for the unique IL-6R a-chain proved
impossible on formalin-fixed material with commercially available
antibodies; however, the expression of gp130 was readily detect-
able in tumors from 77 of the 114 patients (Fig 5D and E). gp130
expression was more common in ABC-DLBCL cases than in GCB-
DLBCL (Fig 5E), with the two subtypes being distinguished by
immunohistochemistry based on the Hans classification, which
takes CD10, BCL-6, and MUM1 expression into account and is
approximately 80% accurate in stratifying the two subsets (Hans
et al, 2004). In conclusion, a subset of DLBCL cell lines and
primary tumors express the IL-6R or its signaling chain, respec-
tively, with a slight bias of expression toward the more aggressive
ABC subtype of the disease.
The constitutive activation of STAT3 is driven by the IL-6/IL-6R
axis in a subset of DLBCL
To address whether DLBCL cell lines not only express the IL-6R but
possibly also produce IL-6, we performed ELISA on culture
supernatants. Only two of the ABC and none of the GCB-DLBCL cell
lines produced IL-6 (Fig 6A). Interestingly, the two (ABC subtype)
cell lines SU-DHL-2 and OCI-Ly3 that produce IL-6 and express
gp130 exhibit constitutive phosphorylation and activation of STAT3
as assessed by Western blotting and flow cytometric analysis of
STAT3 phosphorylation on tyrosine 705 (Fig 6B and C). In contrast,
all other ABC-DLBCL cell lines (with one exception) that express
gp130 activate STAT3 only upon exposure to exogenously added IL-
6 (Fig 6B). None of the GCB-DLBCL cell lines (except SU-DHL-5)
show constitutive STAT3 activation or respond to IL-6 in vitro
despite producing STAT3 at similar levels as the ABC-DLBCL cell
lines (Fig 6D). RC-K8 cells lacking the IL-6R a-chain CD126 due to
genomic editing by CRISPR (Fig EV3A) fail to phosphorylate STAT3
upon addition of IL-6 (Fig 6E). To address whether the constitutive
STAT3 activation that is a hallmark of the IL-6-expressing cell lines
OCI-Ly3 and SU-DHL-2 is indeed due to IL-6, we treated these cells
with an IL-6-specific antibody to neutralize the endogenously
expressed cytokine. Only one cell line (OCI-Ly3), but not the other
(SU-DHL-2), responded to IL-6 neutralization with a reduction in
STAT3 phosphorylation (Fig 6F). Interestingly, SU-DHL-2, but not
OCI-Ly3, cells harbor an inactivating mutation in the suppressor of
cytokine signaling SOCS1; this mutation is known to abrogate the
negative regulation of STAT3 signaling by SOCS1 and to render the
pathway constitutively active (Juskevicius et al, 2018).
To address whether STAT3 phosphorylation in patients corre-
lates with gp130 expression, we evaluated a possible co-expression
of gp130 and phospho-STAT3 in our cohort of DLBCL patients. Of
the 72 patients whose tumors were clearly positive for gp130, 38
(53%) were also positive for phospho-STAT3; of 42 gp130-negative
tumors, only 13 (31%) were positive for phospho-STAT3 (Fig 6G
and H; P = 0.018). The combined results indicate that DLBCL cells,
especially of the ABC subtype, appear to have evolved mechanisms
that ensure STAT3 activation, through either the production of IL-6
or the mutational inactivation of SOCS1. The co-expression of gp130
and phospho-STAT3 in patient biopsies lends further support to this
hypothesis.
IL-6 signaling contributes to MYC-driven lymphomagenesis
in mice
To address in a genetically engineered model of MYC-driven
lymphoma whether IL-6 signaling contributes to the lymphoma
burden, we crossed C57BL/6 mice expressing Cre recombinase
under the activation-induced cytidine deaminase promoter (AID-
Cre) with mice harboring floxed Il6ra alleles, which resulted in a
composite strain lacking IL-6 signaling specifically in the germinal
center (GC) B-cell compartment after immunization with sheep red
blood cells. AID-Cre × Il6rafl/fl mice were additionally crossed with
a mouse strain that expresses MYC under the control of the
immunoglobulin heavy chain enhancer (Emu-MYC) (Adams et al,
1985). Immunization of the resulting offspring induced GC forma-
tion, AID-Cre activity, and Il6ra deletion in GC B cells as reported
previously (Hashwah et al, 2017). In the absence of the MYC trans-
gene, none of the mice of this line developed lymphomas. However,
the majority of mice harboring MYC developed lymphomas in their
axillary and inguinal lymph nodes and spleen, which was somewhat
(not significantly) delayed by the genetic ablation of both copies of
the Il6ra (Fig 7A). Heterozygous mice with one functional copy of
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Il6ra behaved like wild-type mice in this setting (Fig 7A). IL-6ra
deficiency in B cells resulted not only in a delay, but also in a reduc-
tion of the tumor burden, which manifested in significantly smaller
lymph nodes at the study endpoint (Fig 7B). To address whether the
hyperproliferation of B cells undergoing the GC reaction upon sheep
red blood cell immunization was affected by loss of IL-6ra, we
immunized AID-Cre × Il6rafl/fl mice (not harboring the MYC trans-
gene) and their heterozygous and wild-type littermates and quanti-
fied their GC compartment by flow cytometry and Ki67
immunohistochemistry. The immunization led to a strong increase
in CD19+CD95+CD38low GC B cells as determined by flow
cytometry, which was reduced by the deletion of one, and especially
of both alleles of Il6ra (Fig 7C). The smaller GC compartment of
AID-Cre × Il6rafl/fl mice could be attributed to reduced frequencies
of CXCR4hiCD86low centroblasts, whereas CXCR4lowCD86low centro-
cytes were unchanged (Fig 7D and E). We further stained spleen
sections for Ki67 (Fig 7F) and quantified the GC numbers and area;
this approach revealed that the multiplicity of individual GCs as well
as their total area was reduced in mice lacking one or both alleles of
Il6ra (Fig 7G and H). The combined results indicate that IL-6 signal-
ing is GC B-cell-intrinsically required for early-onset, aggressive
lymphomagenesis.
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Figure 5. The IL-6 receptor is expressed on a subset of DLBCL.
A–C The expression of the IL-6Ra (CD126) and signaling chains (gp130) was assessed by flow cytometry (A) and SYBR or TaqMan qRT–PCR (B, C) respectively, on a panel
of DLBCL cell lines. ABC- and GCB-DLBCL cell lines are color-coded in red and green; RC-K8 are depicted in gray, as their subtype is a matter of debate (Kalaitzidis
et al, 2002).
D, E The expression of gp130 in 114 tumor biopsies of DLBCL patients was assessed by immunohistochemistry and correlated with the ABC/non-GCB vs. GCB subtype, as
assessed via the Hans classification. Representative micrographs are shown in (D), alongside the quantification of gp130+ cases among all samples, and among the
two subtypes, in (E). Scale bar, 100 lm.
Data information: The FACS plots in (A) are representative of at least two and up to four independent stainings per cell line. qRT–PCR results are presented as
mean + SEM of two independent experiments. The P-value in (E) was calculated by the chi-square test. n.d., not detectable.
Source data are available online for this figure.
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The IL-6R/gp130/p-STAT3 axis has negative prognostic impact in
both subtypes of DLBCL and can be targeted therapeutically to
reduce the tumor burden in orthotopic models
We and others have reported previously that the phosphorylation of
STAT3 is a common hallmark of DLBCL patients with unfavorable
outcome (Ding et al, 2008; Meier et al, 2009; Ok et al, 2014). We
compiled data from these previous reports to specifically address
the role of phospho-STAT3 expression in relation to DLBCL subtype
and survival probability. Of 814 evaluable patients, 367 were classi-
fied as GCB and 376 were classified as non-GCB/ABC-DLBCL
according to the Hans algorithm (Hans et al, 2004), the subtype
being unknown for 71 patients, who were excluded from subse-
quent analyses. Phospho-STAT3 positivity, defined as expression in
≥ 17% of tumor cells, was not exclusively, but much more
commonly found in ABC-DLBCL tumors, and in more advanced
(stage 3 and 4, relative to stage 1 and 2) disease (Fig 8A). p-STAT3
positivity was a strong negative prognostic factor in the entire
cohort (Fig 8B) and associated with higher overall as well as
disease-specific mortality in both ABC- and GCB-DLBCL subtypes
(Fig 8C and D). To address whether active STAT3 signaling corre-
lated with activity of the JAK2 kinase, which has previously been
implicated in STAT3 phosphorylation in DLBCL (Meier et al, 2009),
we selected 330 cases of which roughly one half was p-STAT3-posi-
tive and the other was p-STAT3-negative. All cases were evaluable
by immunohistochemistry for activated (phosphorylated at
Tyr1007/1008) JAK2 (Fig EV5A). Regression analysis revealed a
positive association between p-STAT3 and pJAK2 (Fig EV5B). Of
p-STAT3-positive cases, the vast majority was also positive for
pJAK2; however, we also detected a large number of pJAK2-positive
cases that were negative for p-STAT3, indicating that additional
factors (STAT3 expression or subcellular localization, for example)
may affect STAT3 phosphorylation (Fig EV5C). The combined
results indicate that the IL-6R/STAT3 signaling axis is preferentially
but not exclusively active in ABC-DLBCL, and a negative prognosti-
cator for both subtypes; STAT3 phosphorylation correlates with acti-
vation of the upstream kinase JAK2.
IL-6R is a therapeutic target in rheumatoid arthritis (RA); a
neutralizing antibody targeting the IL-6R, tocilizumab (trade name:
Actemra), is approved for the treatment of RA in adult patients
(Ogata et al, 2012, 2018) and has also recently received FDA
approval for the treatment of cytokine release syndrome related to
CAR T-cell therapy (Le et al, 2018). We sought to examine a
possible benefit of tocilizumab monotherapy in MISTRG6 mice
that harbor spleen- and bone marrow-colonizing lymphomas due
to intravenous transplantation of serially passaged primary DLBCL
cells; this patient-derived xenograft is positive for the IL-6R and
also positive for phosphorylated STAT3 (Fig 4). Mice received
either an isotype control antibody or tocilizumab starting 2 weeks
after lymphoma cell transplantation. Mice on tocilizumab showed
a reduction of the spleen size at the study endpoint (Fig 8E); the
phosphorylation of STAT3, assessed immunohistochemically on
paraffin-embedded material, was reduced in response to the treat-
ment (Fig 8F). We next examined the effects of tocilizumab on
MISTRG mice transplanted with the cell line OCI-Ly3, which
produces IL-6 (Fig 6A). Indeed, (non-IL-6-expressing) MISTRG
mice harboring OCI-Ly3 cells exhibited detectable levels of hIL-6
in their serum (Fig EV5D). Tocilizumab treatment reduced the
OCI-Ly3 tumor burden in the bone marrow (Fig 8G). In a third
experimental setting, MISTRG6 mice transplanted with RC-K8 cells
were subjected to tocilizumab treatment, which also detectably
reduced the tumor burden (Fig 8H). The combined results from
our patient cohort and xenotransplantation models indicate that
active IL-6R/STAT3 signaling is a negative prognostic factor and
therapeutic target in DLBCL; biomarkers that may be useful in
predicting therapy success include the expression of IL-6R, gp130,
and phospho-STAT3.
Discussion
With this study, we demonstrate that IL-6 signaling is active in a
particularly aggressive subset of DLBCL and supports DLBCL growth
in relevant in vivo models. Before being renamed in 1989 (Kishi-
moto, 1989), IL-6 was referred to as B-cell stimulatory factor 2 (BSF-
2) due to its ability to induce the differentiation of activated B cells
into antibody-producing plasma cells (Kishimoto, 1985). While orig-
inally described as a growth and differentiation factor for normal B
cells, the ability of IL-6 to also stimulate the proliferation of plasma
cell-derived plasmacytoma cell lines (Van Snick et al, 1987) and
primary plasma cell myeloma cells (Anderson et al, 1989) was
discovered shortly thereafter. In contrast, other malignancies
◀ Figure 6. ABC-DLBCL cell lines depend on IL-6 for STAT3 activation.A IL-6 secretion of the indicated cell lines (ABC-DLBCL in red, GCB-DLBCL in green) and primary patient material, as quantified by ELISA and normalized to cell
number (shown per 1,000 cells). n.d., not detectable.
B–D STAT3 phosphorylation as assessed by Western blotting (B, D) and flow cytometry (C) of the indicated ABC-DLBCL and GCB-DLBCL cell lines, with and without 1 h
of exposure to 50 ng/ml hIL-6 (B, D). STAT3 expression levels are shown as Western blot control. Histograms in (C) represent STAT3 phosphorylation in the absence
of exogenously added IL-6.
E STAT3 phosphorylation as assessed by Western blotting of CD126-proficient (WT) or CD126-deficient (ko) RC-K8 cells, with and without 1 h of exposure to 50 ng/ml
hIL-6.
F Kinetics of STAT3 phosphorylation as assessed by Western blotting, of the IL-6-expressing SOCS1wt and SOCS1mut cell lines OCI-Ly3 and SU-DHL-2, under 1-, 6-, and
24-h exposure to an IL-6-neutralizing antibody (a-IL-6, anti-IL-6-neutralizing antibody).
G, H STAT3 phosphorylation and gp130 expression of two representative cases (G) and summarized for the entire cohort of 114 patients (H), as assessed by
immunohistochemistry. The specific p-STAT3 and gp130 signal is seen as brown (DAB staining), and counterstaining was performed using hematoxylin (blue
nuclei). STAT3 phosphorylation is more common in biopsies with gp130 expression; the P-value was calculated by the chi-square test. Scale bar, 100 lm.
Data information: Data in (A) are representative of two experiments and shown as mean + SEM. Data in (B, D, E, and F) were reproduced in three independent
experiments.
Source data are available online for this figure.
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Figure 7. IL-6 signaling contributes to lymphoma development and germinal center B-cell proliferation in a genetically engineered mouse model.
A, B Disease-specific mortality (A) and lymphoma burden as determined by lymph node weight (B), of cohorts of 9–12 mice each (n indicated in the figure) of the
indicated genotypes.
C–H Mice of the indicated genotypes were immunized once with sheep red blood cells and assessed 10 days later by flow cytometry of splenocytes for their frequencies
of GC B cells (C), centroblasts (D), and centrocytes (E). Spleen sections were further stained for Ki67 to reveal GCs (F), which were quantified in both number (G) and
area (H). Arrows in (F) point to GCs; scale bar, 1,000 lm.
Data information: Data in (A and B) are pooled from three (A) and two (B) different litters. Data in (C–H) are pooled from three independent studies. Horizontal
lines indicate medians throughout. Statistical comparisons in (B–H) were performed either by one-way ANOVA (in the case of normal data distribution) or by
non-parametric ANOVA (Kruskal–Wallis test, in the case of non-normal data distribution) with Tukey’s multiple comparisons correction. n is indicated in the figure
panels throughout.
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derived from the B-cell lineage were not previously known to
respond to IL-6. IL-6 signals through its unique ligand-binding IL-
6Ra chain, expressed mainly by hematopoietic cells and
hepatocytes, and the common signal-transducing chain gp130,
which is much more ubiquitously expressed on most cells of the
body and is also engaged by receptors specific for IL-11, IL-27,
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Figure 8. The IL-6 signaling complex is of diagnostic relevance and a therapeutic target in IL-6R+ DLBCL.
A–D Frequency of STAT3 phosphorylation (A), and overall as well as disease-specific survival probability (B), and of overall and disease-specific mortality of DLBCL
patients stratified according to subtype and disease stage (C and D). Of all 814 evaluable patients, 367 were classified as GCB and 376 were classified as non-GCB/
ABC-DLBCL according to the Hans algorithm. Phospho-STAT3 positivity was defined as expression in ≥ 17% of tumor cells and more commonly found in ABC-DLBCL
tumors, and in more advanced (stage 3 and 4, relative to stage 1 and 2) disease (A). p-STAT3 positivity was a strong negative prognostic factor in the entire cohort
(B) and associated with higher overall as well as disease-specific mortality in both ABC- and GCB-DLBCL subtypes (C and D).
E–H Effect of IL-6R neutralization by twice-weekly injection of 250 lg/dose of tocilizumab or an isotype control antibody, starting 2 weeks after tumor cell injection, on
(E and F) the spleen weights of MISTRG6 mice transplanted with 1 × 106 primary DLBCL cells (expanded by one serial passage through MISTRG6 mice), on the
bone marrow lymphoma burden of OCI-Ly3-transplanted MISTRG mice (G), and on the splenic lymphoma burden of RC-K8-transplanted MISTRG6 mice (H), all
assessed at around 4 (G and H) to 8 (E) weeks after tumor cell injection. Representative microscopy images in (F) show STAT3 phosphorylation in spleen-colonizing
primary cells exposed to either tocilizumab or isotype control antibody (in brown, counterstained in blue with hematoxylin), and an H&E-stained section from the
same mouse. TCZ, tocilizumab. Scale bars, 100 lm.
Data information: Results in (E, G, and H) are pooled from two (E and G) or three (H) independent studies each. Horizontal lines indicate medians. P-values were
calculated by the chi-square test (A, C, D), by log-rank test (B), or by the Mann–Whitney test (E, G, H). n is indicated in the figure panels throughout.
Source data are available online for this figure.
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leukemia inhibitory factor, oncostatin M (OSM), ciliary neurotrophic
factor (CNTF), and cardiotrophin 1 (CT1). The signaling pathway is
further complicated by the fact that a soluble form of the IL-6Ra,
generated through proteolytic cleavage by the metalloproteinase
ADAM10 or ADAM17, may also bind to IL-6 and induce signaling in
cells that do not express the membrane-bound form of IL-6Ra. Upon
binding of the (soluble or membrane-bound) IL-6/IL-6Ra complex
to gp130, a gp130-associated Janus kinase (JAK; preferentially
JAK1/2) activates STAT3 through phosphorylation of its tyrosine
residue 705. We report here that DLBCL cells, especially of the ABC
subtype, have evolved several complementary mechanisms that
ensure constitutively active IL-6 signaling. All ABC-DLBCL, but none
of the investigated GCB-DLBCL, cell lines express gp130 at least at
low levels; the expression of gp130 appears to be a prerequisite for
the ability of the cell lines to activate STAT3 upon exposure to IL-6,
as none of the GCB cell lines showed STAT3 phosphorylation upon
IL-6 treatment, despite expressing copious amounts of STAT3 itself.
Two-thirds of a patient cohort of 114 patients were positive for
gp130 as determined by immunohistochemistry, again with a clear
bias of expression toward the ABC-DLBCL subtype. A second adap-
tation of ABC-DLBCL that is consistent with the putative depen-
dence of this subtype on IL-6 is the production and secretion of the
cytokine itself. The main cellular source of IL-6 in the steady state
and in settings of infection, inflammation, and carcinogenesis is
now widely believed to be of myeloid origin; however, normal B
cells and plasma cell myeloma cells may also produce IL-6 and bind
it in an autocrine manner. Our in vitro experiments clearly revealed
that only IL-6-expressing cell lines show constitutive STAT3 activa-
tion, which in turn is abrogated by neutralization of IL-6. Again, the
analysis of gp130 and phospho-STAT3 co-expression in our patient
cohort confirmed that active STAT3 is more commonly (but not
exclusively) observed in gp130-expressing DLBCL. As STAT3 signals
not only downstream of gp130, but also downstream of the recep-
tors for IL-10, type I interferons, and EGF, it is conceivable and even
likely that alternative microenvironmental signals may contribute to
STAT3 activation in the context of DLBCL. A third adaptation of
ABC-DLBCL cells attesting to their dependence on constitutive
STAT3 activation is the mutational inactivation of SOCS1. SOCS1
negatively regulates STAT3 phosphorylation downstream of gp130;
indeed, the only ABC-DLBCL cell line in our panel that harbors an
inactivating SOCS1 mutation (Juskevicius et al, 2018) was indepen-
dent of IL-6 with respect to its constitutive STAT3 activation. SOCS1
mutations are rather common in DLBCL; in a patient cohort of 138
primary untreated DLBCL patients that we subjected to targeted
high-throughput sequencing of either all exons or the hotspots of 68
frequently mutated genes in B-cell lymphomas, SOCS1 mutations
emerged as the second most common mutation, affecting 28% of
patients (Juskevicius et al, 2017). Forty-seven different mutations,
the vast majority predicted to be deleterious for protein synthesis or
function, of SOCS1 were detected in 21 patients, of which 12 were
classified as non-GCB and 9 as GCB-DLBCL (Juskevicius et al,
2017). Other studies have reported similar frequencies, with 16
(Schif et al, 2013) to 27% (Mottok et al, 2009) of patients harboring
SOCS1 mutations.
As a consequence of their dependence on IL-6, DLBCL cell lines
and primary cells expressing the IL-6R benefit from a microenvi-
ronment that provides access to the cytokine. MISTRG mice
expressing human IL-6 from an allele knocked into the
endogenous murine locus, and MISTRG mice reconstituted with a
normal human immune system, have emerged in this study as
terrific hosts for DLBCL engraftment, with involvement of the bone
marrow, spleen, and various internal organs. Cell lines that
express the IL-6Ra (RC-K8) colonize primary and secondary
lymphoid tissues of MISTRG6 mice at much higher levels than
those of MISTRG mice; the same is true for primary cells, which
do not engraft at all in the absence of IL-6. We engineered our cell
lines to express luciferase, which allowed us to track them, and to
quantify the tumor burden over time. The examined DLBCL cell
lines all showed unique and highly reproducible tissue tropisms
that in some instances may be reflective of the parental tumors.
RC-K8 cells, for example, initially grow mostly in the jaw bone,
and only later, and in the presence of IL-6, will disseminate to
other bones and organs. The orthotopic growth of the cell lines in
both lymphoid and non-lymphoid organs is reflective of the
heterogeneity of human DLBCL, which may arise at, or dissemi-
nate to, many different sites, including the gastrointestinal tract,
reproductive organs, and brain. Due to its versatility, ease of use
not requiring surgery, rapid disease course, and traceability by
IVIS, this novel model lends itself to a variety of applications,
including (co-clinical) drug susceptibility testing. We have used
the model to deliver proof of concept that targeting the IL-6 signal-
ing pathway is a promising strategy for the treatment of IL-6R+/
phospho-STAT3+ cases of DLBCL. The antibody we used for this
purpose, tocilizumab, is a humanized anti-IL-6Ra monoclonal Ab
of the IgG1 class that was generated by grafting the complementar-
ity-determining regions of a mouse anti-human IL-6R Ab onto
human IgG1 (Sato et al, 1993). It blocks IL-6-mediated signal
transduction by inhibiting IL-6 binding to the transmembrane and
soluble forms of IL-6Ra. The efficacy, excellent tolerability, and
safety of tocilizumab have been verified in numerous clinical trials
resulting in the approval of this biologic for the treatment of RA
(Tanaka et al, 2014), juvenile idiopathic arthritis (Yokota et al,
2008, 2012), and Castleman’s disease (Nishimoto et al, 2008), the
latter being a non-cancerous disorder of the lymph nodes charac-
terized by non-clonal hyperproliferation of B cells resulting from
IL-6 hypersecretion. The latest indication for which tocilizumab
has been approved is severe cytokine release syndrome due to
CAR T-cell therapy (Teachey et al, 2013; Le et al, 2018). Although
the early findings describing the IL-6 dependence of plasma cell
myeloma cells had generated a strong interest in the IL-6 signaling
complex as a therapeutic target in this disease, the initial clinical
trials were disappointing; a phase II trial in high-risk smoldering
myeloma patients is ongoing (Matthes et al, 2016).
In conclusion, we show here that a sizable fraction of DLBCL
patients, especially of the ABC subtype, exhibit hallmarks of aber-
rant activation of the IL-6 signaling pathway which constitutes a
promising therapeutic target in this population. Tumors with puta-
tive susceptibility to IL-6 inhibition can be identified based on their
IL-6R expression and phospho-STAT3 positivity, which is readily
detectable by flow cytometry or immunohistochemistry and is asso-
ciated with a dismal prognosis. SOCS1 mutations anywhere in the
only exon of the gene would counter-indicate treatment success. In
summary, we propose here a novel driver of DLBCL growth that can
be therapeutically targeted with a safe and well-tolerated biologic
response modifier that is approved for a variety of unrelated indica-
tions in humans.
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Materials and Methods
Cell culture experimentation and ELISA
The DLBCL cell lines used here included six of GCB-DLBCL
subtype (SU-DHL-4, SU-DHL-5, SU-DHL-6, SU-DHL-8, SU-DHL-10,
and SU-DHL-16) and five of ABC-DLBCL subtype (U-2932, OCI-
Ly3, OCI-Ly10, SU-DHL2, and RIVA) and one unclassified cell line
(RC-K8) that have all been described previously (Hashwah et al,
2017; Stelling et al, 2018) and are routinely tested, and negative,
for mycoplasma. Cell line authentication was performed according
to the guidelines of the International Cell Line Authentication
Committee using short tandem repeat profiling; the result of this
effort was described recently for all cell lines used here, along
with their sources (Juskevicius et al, 2018). Cell lines were main-
tained at 37°C and 5% CO2 in a humidified atmosphere in IMDM
(RIVA, OCI-Ly3, OCI-Ly10) or RPMI (SU-DHL2 and SU-DHL5)
supplemented with 20% (SU-DHL-4, SU-DHL-6, SU-DHL-10, SU-
DHL-16, RC-K8, U-2932) or 10% (all others) heat-inactivated FBS
and antibiotics. Cells in culture were treated with 50 ng/ml of
human recombinant IL-6 (Stemcell Technologies), and super-
natants were collected 1 h after treatment and used for protein
extraction. For neutralization of human IL-6 bioactivity, anti-
human IL-6 antibody (MQ2-13A5) or Rat IgG1j Isotype Ctrl
(RTK2071) antibodies (Biolegend) were used at final concentra-
tions of 8 lg/ml. The levels of secreted IL-6 in culture super-
natants and in mouse serum were determined by assaying
supernatants collected from cells seeded at 400,000/ml 2 days
earlier or from serum harvested at euthanasia with the Human
IL-6 ELISA Kit (Thermo).
Lentiviral gene transfer and genomic editing
A lentiviral approach was used to generate luciferase-expressing
DLBCL cell lines. Lentiviral packaging was performed in HEK 293T
cells (cultured in DMEM (Gibco) supplemented with 10% FBS and
100 U/ml penicillin and 100 lg/ml streptomycin) by polyethylen-
imine transfection (PEI, Polysciences, MW 25000). In brief, for
each transfection, 4 lg of viral plasmid pHIV-Luc-ZsGreen
(Addgene plasmid #39196), 2 lg of helper plasmid psPAX2
(Addgene plasmid #12260), and 1 lg of envelope plasmid pCMV-
VSV-G (Addgene plasmid #8454) were used. DLBCL cell lines were
infected with lentiviral particles by spinoculation at 32°C and
800 × g for 60 min in the presence of 5 lg/ml polybrene (hexadi-
methrine bromide; Sigma-Aldrich). Transduced cells (high
ZsGreen-expressing) were sorted using a FACSAria III at day 6 after
transduction. CRISPR/Cas9 genomic editing of the IL6RA gene
(encoding the IL-6R a-chain CD126) in RC-K8 cells was achieved
by electroporation. The PX458 plasmid used was obtained from
Addgene (#48138: pSpCas9 (BB)-2A-GFP). The IL6RA guide
(sequence: GTCGGTGCAGCTCCACGACTC) targeting the second
exon of the gene was cloned into the PX458 vector. Nucleoporation
of 1 × 106 RC-K8 cells was performed with 0.5–3 lg DNA using the
Amaxa Nucleofector II device. At 48 h post-transfection, cells were
sorted based on their GFP expression; this first sort was followed
by two subsequent sorts (at 1 and 2 weeks post-transfection) for
CD126+ and CD126 fractions, which were tested side by side in
all experiments. Sorted bulk cells were subjected to flow cytometric
verification of the CD126 knockout using a specific antibody (clone
UV4; Biolegend).
Animal experimentation, reconstitution, in vivo imaging, and
tissue processing and staining
M-CSFh;IL-3/GM-CSFh;hSIRPAtg;TPOh;Rag2;cc (MISTRG; Rong-
vaux et al, 2014) and MISTRG mice additionally expressing IL-6h
(MISTRG6; Das et al, 2016) were obtained from a local repository.
For xenotransplantation studies, cell lines were injected subcuta-
neously (1 × 107 cells in 150 ll PBS) into both flanks of 6- to 8-
week-old mixed-gender MISTRG mice, or intravenously (1 × 107
cells in 100 ll PBS) into mixed-gender MISTRG or MISTRG6 mice in
the orthotopic model. Once palpable tumors had formed in the
subcutaneous model (~ 40 mm3), the volume of the tumors was
measured by calipers and calculated using the formula (a2 × b)/2,
where a is the shorter and b the longer tumor dimension. For
whole-body bioluminescent imaging of mice included in the ortho-
topic model, mice were i.p. injected with D-luciferin (150 mg/kg;
VivoGlo Luciferin; Promega) and mice were analyzed 10 min later
using an IVIS Spectrum system (Caliper LifeSciences). Biolumines-
cence images were acquired using “auto” setting with F/stop = 1
and binning = medium. A digital false-color photon emission image
of the mouse was generated, and photons were counted within the
whole-body area. Photon emission was measured as radiance in
p/s/cm2/sr. At the study endpoint of orthotopic models, spleens
were harvested and weighed, and hind legs/jaw bones were
collected for the analysis of the bone marrow. Tissue colonization
by lymphoma cells was assessed for the liver, kidney, lung, and
reproductive organs after removal from the carcass using two
complementary approaches: Livers and kidneys were first macro-
scopically inspected for the appearance of white nodules indicative
of tumor growth, and then placed individually, alongside the lung
lobes and ovaries or testicles into 12-well plates filled with luciferin
in PBS (300 lg/ml) for ex vivo IVIS imaging. Organs were imaged
within 5 min of euthanasia. For the reconstitution of mice with a
human immune system, 2- to 4-day-old pups were irradiated with a
sublethal dose of 1 Gray and intrahepatically injected with 100,000–
250,000 immunomagnetically isolated CD34+ cord blood-derived
hematopoietic stem cells as described previously (Arnold et al,
2017). Reconstituted mice were included in experiments at 6 weeks
of age. Anti-human CD4 (OKT-4), mouse IgG2b isotype control,
anti-mouse/human/rat CCL2 (2H5), and polyclonal Armenian
hamster IgG antibodies were purchased from BioXCell. Mice were
administered a 500 lg dose 1 day before subcutaneous injection of
tumor cells, then once or twice per week with a 250 lg of anti-
human CD4 or anti-CCL2, respectively, until the end of the study
(d27).
For patient-derived xenograft transplantation, bone marrow
mononuclear cells (MNCs) containing DLBCL cells (obtained from
Clinic of Hematology-Oncology at the University of Zu¨rich) were
intravenously injected into MISTRG6 mice. Lymphoma cells
engrafted in the spleen were serially transplanted (1–2 × 106 cells)
to MISTRG and MISTRG6 mice, and 8 weeks after tumor cell injec-
tion, bone marrow of hind legs and spleens were harvested and
analyzed by flow cytometry. Treatment with recombinant anti-
human CD126 antibody (Actemra, Roche) and recombinant human
IgG1 isotype control antibody (BioXCell, BE0297) was performed
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two times per week. During the first week of treatment for each
injection, 500 lg of the respective antibody was administered i.p.
During the remaining study period, mice were injected with 250 lg
antibody per dose. Serially transplanted patient material was
enriched for human B cells using the MagniSortTM Human CD19
Positive Selection Kit (Thermo). Cells were then either used for RNA
extraction or cultured for 2 days in RPMI 1640 (supplemented with
20% FBS, 1 mM sodium pyruvate, non-essential amino acids,
100 U/ml penicillin, 100 lg/ml streptomycin) for ELISA. For qRT–
PCR-based determination of gp130 and IL-6RA expression, bone
marrow MNCs containing DLBCL cells were enriched for human B
cells as described above and then subjected to RNA extraction and
qRT–PCR (see below).
The mouse strains B6;SJL-Il6ratm1.1Drew/J, B6.Cg-Tg(IghMyc)
22Bri/J, and B6;129P2-Aicdtm1CreMnz/J were obtained from the
Jackson Laboratories. Il6rafl/fl mice were crossed to AIDcre animals
and MYC-transgenic mice to obtain composite strains. For longitudi-
nal monitoring of MYC-transgenic mice, 6- to 8-week-old mice were
immunized at regular 14-d intervals with an i.p injection of 200 ll
of 10% sheep red blood cells (Innovative Research) and monitored
for clinical symptoms and enlarged lymph nodes indicating
lymphoma development within a period of 100 days. Moribund
mice were euthanized, and their spleens as well as inguinal and
axillary lymph nodes were weighed. For immunization studies, mice
received a single dose of 100 ll of 4% sheep red blood cells intra-
venously and were analyzed for germinal center formation 10 days
later. Splenocytes were treated with ACK red blood cell lysis buffer
pH 7.2–7.4 (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA)
and passed through a 40-lM cell strainer to produce single-cell
suspensions. Cells were subsequently stained using the following
fluorescent-labeled anti-mouse antibodies: PE-Cy7-conjugated anti-
CD95/FAS (Jo2; Becton Dickinson), PerCP-Cy5.5-conjugated anti-
CD86 (GL-1; Biolegend), Fixable Viability Dye eFluor 780, APC-
conjugated anti-CD19 (eBio1D3), FITC-conjugated anti-CD38 (90),
and PE-conjugated anti-CXCR4 (2B11), all from eBio/Affymetrix.
Data were acquired on CyAn ADP (Beckman Coulter) or LSRFor-
tessa (BD) flow cytometers and analyzed with the FlowJo software
package (TreeStar). For Ki67 staining of germinal centers, CONFIRM
anti-Ki-67 (30-9) Rabbit Monoclonal Primary Antibody (Roche) was
used for staining of proliferating cells within germinal centers on
formalin-fixed paraffin-embedded spleen sections using a Ventana
automated slide stainer. One longitudinal section was assessed per
mouse spleen. The images were acquired on a Leica microscope,
and ImageJ was used for area assessment. Germinal centers were
identified as Ki67-positive areas within blue areas. All animal stud-
ies were reviewed and approved by the Zu¨rich Cantonal Veterinary
Office (licenses 227/2015, 235/2015). Ethical approval for work
with primary DLBCL cells was obtained from the Ethical Commis-
sion of the Canton of Zurich (KEK-ZH-Nr. 2009-0062/1). Informed
consent was obtained from all subjects, and all experiments using
human material conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report.
Western blotting
Protein extracts were made in RIPA buffer (50 mM Tris–HCl, pH 8.0,
150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS) supplemented with 2 mM sodium orthovanadate,
15 mM sodium pyrophosphate, 10 mM sodium fluoride, and 1×
cOmplete protease inhibitor cocktail (Roche). Protein concentrations
were determined using BCA assay (Pierce), and equal amounts were
separated by SDS–PAGE (4–20% Mini-PROTEAN TGXTM Precast
Protein Gels; BIO-RAD) followed by transfer onto nitrocellulose
membranes. Membranes were probed with antibodies against a-
tubulin (DM1A, Sigma-Aldrich; 1:3,000 dilution), STAT3 (79D7, Cell
Signaling Technology; 1:2,000), p-STAT3 (Tyr705, Cell Signaling
Technology; 1:1,000), gp130 (E-8, Santa Cruz; 1:1,000), and b-actin
(8H10D10, Cell Signaling Technology; 1:3,000).
Flow cytometric analysis
Cells isolated from mouse spleens or bone marrow (jaw bones or
femoral bones) were treated with ACK red blood cell lysis buffer pH
7.2–7.4 (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA) and
passed through a 40-lM cell strainer to produce single-cell suspen-
sions. Cells were subsequently stained using the following fluores-
cent-labeled antibodies which were all purchased from Biolegend
(clone numbers in brackets) and used at 1:100 dilution unless other-
wise specified: Fixable Viability Dye eFluor 780 eBio/Affymetrix
(1:1,000), and Hu FCR binding inhibitor purified, APC anti-human
CD45 (2D1), PE anti-mouse CD45 (30-F11), APC anti-human CD19
(HIB19), PE-Cy7 anti-human NKp46 (9E2), and PB anti-human
CD20 (HI47), all from Thermo; and purified rat anti-mouse CD16/
CD32 (93), PB anti-mouse CD45 (30-F11), PB anti-human CD45
(HI30), PerCP-Cy5.5 anti-human CD33 (P67.6), BV605 anti-human
CD3 (UCHT1), PE anti-STAT3 Phospho Tyr705 (13A3-1), PE anti-
mouse IgG1j (MOPC-21), APC anti-human Ig light chain lambda
(MHL-38), PE anti-human Ig light chain lambda (MHL-38), PE anti-
human Ig light chain kappa (MHK-49), FITC anti-human Ig light
chain kappa (MHK-49), and PB anti-human CD19 (HIB19), all from
Biolegend. For immunophenotyping of DLBCL cell lines, cells were
stained with APC anti-human CD130 (2E1B02), APC mouse IgG2a
kappa isotype ctrl (MOPC-173), APC anti-human CD126 (UV4), PE
anti-human CD126 (UV4), APC mouse IgG1 kappa isotype ctrl
(MOPC-21), PE mouse IgG1 kappa isotype ctrl (MOPC-21), and PE
anti-STAT3 Phospho Tyr705 (13A3-1; 1:10 dilution) (all from Biole-
gend). Data were acquired on CyAn ADP (Beckman Coulter) or
LSRFortessa (BD) flow cytometers and analyzed with the FlowJo
software package (TreeStar).
Quantitative RT–PCR
RNA was extracted using the NucleoSpin RNA kit (Macherey-
Nagel). One microgram of total RNA was reverse-transcribed using
SuperScript III reverse transcriptase (Invitrogen). For qRT–PCR,
LightCycler 480 SYBR Green Master I (Roche) or TaqMan Gene
Expression Assays (Thermo Fisher Scientific) were used, followed
by analysis on a LightCycler 480 instrument. Samples were
measured in duplicate. For the SYBR primer pairs, the efficiency
was calculated by performing dilution series experiments. Target
mRNA abundance was subsequently calculated relative to human
RPLP32. The primers used were as follows: RPLP32, fwd: GAA GTT
CCT GGT CCA CAA CG, rev: 50-GCG ATC TCG GCA CAG TAA G;
and IL6-R, fwd: CAC ATT CCT GGT TGC TGG AG, rev: GCT TCC
ACG TCT TCT TGA ACC. For TaqMan assays, proprietary probes
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spanning exons 13–14 of the IL-6 signal transducer/gp130 (IL6ST:
Hs00174360_m1) and binding to exon 1 of actin (ACTB:
Hs99999903_m1), respectively, were used.
Immunohistochemistry
Cumulative data of three independent DLBCL study cohorts were
used for in silico analysis of the prognostic role of p-STAT3 expres-
sion. All cases have been stained utilizing the Cell Signaling anti-
body clone D3A7 mAb9145 at a 1:50 dilution. The cutoff to assign
positivity has been set at > 17% staining tumor cells as estimated
by receiver operating characteristic analysis taking survival as a set
variable. The antibody used for phospho-JAK2 (Tyr1007/1008)
staining was the Cell Signaling antibody clone C80C3 mAb3776
(1:50 dilution), and the cutoff to assign positivity has been set at
> 2.5% positively staining tumor cells. Overall and disease-specific
survival were measured from initial diagnosis to death of any
cause or on/with lymphoma, respectively, or last follow-up. The
probability of survival was determined using the Kaplan–Meier
method, and differences were compared using the log-rank with
the help of the Statistical Package for the Social Sciences (IBM
SPSS version 22.0, Chicago, IL, USA). Two of the above study
collectives were stained for the IL-6R subunit gp130 applying the
Abcam polyclonal antibody ab170257 at a 1:200 dilution. The
cutoff to assign positivity was set at > 30% positively staining
tumor cells taking p-STAT3 positivity as a set variable. The correla-
tion between expression of both p-STAT3 and gp130 was estimated
using the chi-square test.
Statistics
All statistical analyses were performed using GraphPad Prism soft-
ware. Graphs represent means plus SD of at least two independent
experiments, and statistical analysis was performed using two-tailed
Mann–Whitney test for in vivo studies and correlation analysis was
performed using one-way ANOVA. A log-rank test was performed
for comparison of survival curves.
Expanded View for this article is available online.
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The paper explained
Problem
Diffuse large B-cell lymphoma is an aggressive and often fatal B-cell
malignancy for which targeted therapies other than the CD20-specific
antibody rituximab are not available. Large-scale multi-omics studies
have recently shed light on the mutational, epigenetic, and transcrip-
tional landscapes of the disease. The development of animal models
in which cell lines or patient samples could be screened pre- or co-
clinically for drug susceptibilities, and in which the relevance of aber-
rantly inactivate or hyperactive signaling pathways could be exam-
ined, is woefully lagging behind.
Results
In this work, we describe a useful and highly reproducible model of
DLBCL cell line and primary cell xenotransplantation that exploits
genetically humanized “MISTRG” mice, which harbor human knock-in
alleles encoding cytokines and growth factors for various human leuko-
cyte subsets. We further humanized MISTRG mice by reconstituting
them at birth with a normal human immune system, which required
their transplantation with human CD34+ hematopoietic stem and
progenitor cells. MISTRG mice that had been humanized in this manner
or that had additionally been genetically modified to express human
IL-6 from a knock-in allele turned out to be even better hosts for DLBCL
cell lines and primary cells, which, upon intravenous injection,
engrafted in the bone marrow, spleen, and non-lymphoid tissues such
as kidneys, liver, and lung. Labeling of our cell lines with luciferase
further allowed us to track them in their murine hosts over time.
The contribution of IL-6 raised the question whether DLBCL cell
lines generally require this cytokine for growth. In the course of exten-
sive studies in vitro and in vivo, we found that most DLBCL cell lines
of the (histologically specified) ABC-DLBCL subtype express both
chains of the IL-6 receptor, with some of them even producing their
own cytokine to stimulate an autocrine pro-proliferative loop. Others
had inactivating mutations in a negative regulator of IL-6 signaling,
SOCS1, which explained why they had become independent of exoge-
nous addition of the cytokine. We were indeed able to confirm that a
cell line producing IL-6 did not benefit from, or require, human IL-6
expression for growth in MISTRG mice. Similar findings were obtained
in genetically engineered mice that lack IL-6 signaling specifically in
the B-cell compartment and are largely protected from aberrant B-cell
hyperproliferation and lymphomagenesis.
Impact
We propose that our findings have clinical impact for patients with
DLBCL that is positive for the IL-6 receptor and also positive for phos-
phorylated STAT3, which acts downstream of IL-6 signaling and has
been known for a number of years to be a strong negative predictor
of DLBCL patient survival.
An IL-6R-specific antibody, named tocilizumab, exists and is
approved and marketed for human use in patients with rheumatoid
arthritis and in patients suffering from cytokine release syndrome after
CAR T-cell therapy. We used this antibody to demonstrate in our
lymphoma-bearing mice that blocking the IL-6R slows tumor growth
and comes with virtually no side effects to the mice. We believe that
DLBCL patients with IL-6R-positive, STAT3-positive DLBCL that are wild
type for SOCS1 and perhaps also produce IL-6 should qualify to receive
this antibody, ideally as a combination therapy with other targeted
agents that are emerging from clinical trials. In summary, we propose
that targeting the IL-6 signaling pathway represents an opportunity for
personalized treatment that should be explored in clinical trials in
DLBCL patients.
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non-hodgkin-lymphoma/other-non-hodgkin-lymphomas/diffuse-large-b-cell-
lymphoma/
https://www.mayoclinic.org/diseases-conditions/lymphoma/symptoms-causes/
syc-20352638
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